Jon S Saxe - Net Worth and Insider Trading
Jon S Saxe Net Worth
The estimated net worth of Jon S Saxe is at least $29,140 dollars as of 2024-04-27. Jon S Saxe is the Director of Durect Corp and owns about 17,781 shares of Durect Corp (DRRX) stock worth over $16,559. Jon S Saxe is the Director of Vistagen Therapeutics Inc and owns about 1,775 shares of Vistagen Therapeutics Inc (VTGN) stock worth over $8,431. Jon S Saxe is also the Director of PDL BioPharma Inc and owns about 1,680 shares of PDL BioPharma Inc (PDLI) stock worth over $4,150. Details can be seen in Jon S Saxe's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jon S Saxe has not made any transactions after 2020-08-21 and currently still holds the listed stock(s).
Transaction Summary of Jon S Saxe
Jon S Saxe Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jon S Saxe owns 6 companies in total, including Vistagen Therapeutics Inc (VTGN) , Durect Corp (DRRX) , and SciClone Pharmaceuticals Inc (SCLN) among others .
Click here to see the complete history of Jon S Saxe’s form 4 insider trades.
Insider Ownership Summary of Jon S Saxe
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
VTGN | Vistagen Therapeutics Inc | 2020-08-21 | director |
DRRX | Durect Corp | 2019-06-10 | director |
SCLN | SciClone Pharmaceuticals Inc | 2017-10-13 | director |
PDLI | PDL BioPharma Inc | 2008-04-09 | director |
INSV | InSite Vision Inc | 2007-12-10 | director |
INCY | Incyte Corp | 2004-03-30 | director |
Jon S Saxe Latest Holdings Summary
Jon S Saxe currently owns a total of 3 stocks. Among these stocks, Jon S Saxe owns 17,781 shares of Durect Corp (DRRX) as of June 10, 2019, with a value of $16,559 and a weighting of 56.83%. Jon S Saxe owns 1,775 shares of Vistagen Therapeutics Inc (VTGN) as of August 21, 2020, with a value of $8,431 and a weighting of 28.93%. Jon S Saxe also owns 1,680 shares of PDL BioPharma Inc (PDLI) as of April 18, 2006, with a value of $4,150 and a weighting of 14.24%.
Latest Holdings of Jon S Saxe
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
DRRX | Durect Corp | 2019-06-10 | 17,781 | 0.93 | 16,559 |
VTGN | Vistagen Therapeutics Inc | 2020-08-21 | 1,775 | 4.75 | 8,431 |
PDLI | PDL BioPharma Inc | 2006-04-18 | 1,680 | 2.47 | 4,150 |
Holding Weightings of Jon S Saxe
Jon S Saxe Form 4 Trading Tracker
According to the SEC Form 4 filings, Jon S Saxe has made a total of 4 transactions in Durect Corp (DRRX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Durect Corp is the acquisition of 2,500 shares on June 10, 2019, which cost Jon S Saxe around $13,750.
According to the SEC Form 4 filings, Jon S Saxe has made a total of 1 transactions in Vistagen Therapeutics Inc (VTGN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Vistagen Therapeutics Inc is the acquisition of 1,000 shares on August 21, 2020, which cost Jon S Saxe around $20,700.
According to the SEC Form 4 filings, Jon S Saxe has made a total of 0 transactions in PDL BioPharma Inc (PDLI) over the past 5 years. The most-recent trade in PDL BioPharma Inc is the sale of 5,000 shares on April 18, 2006, which brought Jon S Saxe around $150,050.
Insider Trading History of Jon S Saxe
- 1
Jon S Saxe Trading Performance
GuruFocus tracks the stock performance after each of Jon S Saxe's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jon S Saxe is 47.24%. GuruFocus also compares Jon S Saxe's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jon S Saxe within 3 months outperforms 6 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jon S Saxe's insider trading performs compared to the benchmark.
Performance of Jon S Saxe
Average Return
151.06%
Outperforming Transactions
91%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 1.16 | 47.24 | 128.15 | 151.06 | 38.89 | -1.6 |
Relative Return to S&P 500(%) | -1.56 | 44.1 | 118.78 | 142.45 | 19.96 | -13.94 |
Jon S Saxe Ownership Network
Ownership Network List of Jon S Saxe
Ownership Network Relation of Jon S Saxe
Jon S Saxe Owned Company Details
What does Vistagen Therapeutics Inc do?
Who are the key executives at Vistagen Therapeutics Inc?
Jon S Saxe is the director of Vistagen Therapeutics Inc. Other key executives at Vistagen Therapeutics Inc include Chief Operating Officer Joshua S. Prince , CHIEF FINANCIAL OFFICER Cynthia Lynn Anderson , and 10 percent owner Commodore Capital Lp .
Vistagen Therapeutics Inc (VTGN) Insider Trades Summary
Over the past 18 months, Jon S Saxe made no insider transaction in Vistagen Therapeutics Inc (VTGN). Other recent insider transactions involving Vistagen Therapeutics Inc (VTGN) include a net purchase of 775,756 shares made by Commodore Capital Lp ,
In summary, during the past 3 months, insiders sold 0 shares of Vistagen Therapeutics Inc (VTGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vistagen Therapeutics Inc (VTGN) were sold and 775,756 shares were bought by its insiders, resulting in a net purchase of 775,756 shares.
Vistagen Therapeutics Inc (VTGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Vistagen Therapeutics Inc Insider Transactions
Jon S Saxe Mailing Address
Above is the net worth, insider trading, and ownership report for Jon S Saxe. You might contact Jon S Saxe via mailing address: First Horizon Pharmaceutical Corp, 660 Hembree Pkwy Ste 106, Roswell Ga 30076.